Xeris Biopharma Holdings, Inc. - Common Stock (XERS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
XERS on Nasdaq
Shares outstanding
165,974,436
Price per share
$7.52
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
100,827,262
Total reported value
$791,486,867
% of total 13F portfolios
0%
Share change
+3,346,929
Value change
+$25,419,628
Number of holders
223
Price from insider filings
$7.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 6.7% $87,815,414 11,186,677 The Vanguard Group 31 Dec 2025

As of 31 Dec 2025, 223 institutional investors reported holding 100,827,262 shares of Xeris Biopharma Holdings, Inc. - Common Stock (XERS). This represents 61% of the company’s total 165,974,436 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) together control 45% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.6% 12,639,318 +6% 0% $99,218,645
VANGUARD GROUP INC 6.7% 11,186,677 +14% 0% $87,815,416
D. E. Shaw & Co., Inc. 4.6% 7,574,850 +30% 0.05% $59,462,573
GEODE CAPITAL MANAGEMENT, LLC 2.6% 4,275,989 +3.3% 0% $33,571,396
STATE STREET CORP 2.5% 4,116,924 +10% 0% $32,317,853
Qube Research & Technologies Ltd 2.1% 3,498,197 +6.8% 0.04% $27,460,846
Driehaus Capital Management LLC 1.8% 2,980,567 +14% 0.16% $23,397,451
Nuveen, LLC 1.7% 2,806,806 -0.75% 0.01% $22,033,428
MORGAN STANLEY 1.6% 2,707,783 -16% 0% $21,256,104
WELLINGTON MANAGEMENT GROUP LLP 1.4% 2,286,598 +294% 0% $17,949,794
Rosalind Advisors, Inc. 1.3% 2,111,700 +18% 6.4% $16,576,845
TWO SIGMA INVESTMENTS, LP 1% 1,732,667 +7.3% 0.02% $13,601,436
Parkman Healthcare Partners LLC 1% 1,691,585 -5.6% 1.3% $13,278,942
GOLDMAN SACHS GROUP INC 0.94% 1,568,421 -13% 0% $12,312,105
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.85% 1,403,824 -3% 0% $11,020,018
Legal & General Group Plc 0.84% 1,396,265 +2.9% 0% $10,954,263
CenterBook Partners LP 0.84% 1,391,590 +99% 0.53% $10,923,982
NORTHERN TRUST CORP 0.84% 1,386,829 +1.7% 0% $10,886,607
Granahan Investment Management, LLC 0.74% 1,223,404 +249% 0.41% $9,603,721
KENNEDY CAPITAL MANAGEMENT LLC 0.73% 1,213,969 +0.2% 0.2% $9,529,657
Connor, Clark & Lunn Investment Management Ltd. 0.64% 1,058,692 -38% 0.02% $8,310,732
ACADIAN ASSET MANAGEMENT LLC 0.59% 971,598 +5.5% 0.01% $7,622,000
Knott David M Jr 0.58% 970,000 -4.4% 3.5% $7,614,500
AQR CAPITAL MANAGEMENT LLC 0.58% 957,579 -2.6% 0% $7,516,995
DEUTSCHE BANK AG\ 0.57% 940,592 -40% 0% $7,383,647

Institutional Holders of Xeris Biopharma Holdings, Inc. - Common Stock (XERS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 100,827,262 $791,486,867 +$25,419,628 $7.85 223
2025 Q3 96,902,264 $788,823,196 +$58,407,958 $8.14 229
2025 Q2 90,495,534 $422,617,978 +$16,622,096 $4.67 200
2025 Q1 86,799,982 $476,523,606 +$123,713,876 $5.49 199
2024 Q4 65,548,446 $222,208,577 +$5,693,687 $3.39 161
2024 Q3 63,918,467 $182,169,401 +$11,712,690 $2.85 143
2024 Q2 60,623,914 $136,403,872 +$57,516 $2.25 132
2024 Q1 60,495,199 $133,691,334 +$1,259,202 $2.21 140
2023 Q4 59,921,867 $140,817,138 +$3,980,290 $2.35 118
2023 Q3 55,319,172 $102,889,496 -$2,383,422 $1.86 109
2023 Q2 55,920,487 $146,506,955 +$17,809,976 $2.62 101
2023 Q1 49,463,144 $80,622,599 -$5,927,964 $1.63 89
2022 Q4 53,916,182 $71,703,555 -$5,395,029 $1.33 93
2022 Q3 57,306,752 $89,403,802 -$3,332,109 $1.56 97
2022 Q2 59,291,260 $91,305,115 +$12,225,836 $1.54 95
2022 Q1 50,404,861 $129,034,768 +$23,839,809 $2.56 97
2021 Q4 40,971,724 $120,062,000 +$117,961,261 $2.93 85
2021 Q3 704,170 $1,725,000 +$1,725,000 $2.45 1